Eur Rev Med Pharmacol Sci 2018; 22 (6): 1770-1775

DOI: 10.26355/eurrev_201803_14595

Effects of sevoflurane post-conditioning in cerebral ischemia-reperfusion injury via TLR4/NF-κB pathway in rats

C.-X. Shi, Y.-B. Ding, F. Yu J. Jin, T. Li, J.-H. Ma, L.-Y. Qiao, W.-Z. Pan, K.-Z. Li

Department of Anesthesiology, School of Medicine, Shandong University, Jinan, Shandong, China. likezhong2018@outlook.com


OBJECTIVE: The aim of the study was to investigate the anti-inflammatory effect of sevoflurane post-conditioning on cerebral ischemia-reperfusion injury in rats.

MATERIALS AND METHODS: Thirty Sprague Dawley (SD) rats were randomly divided into 3 groups: sham operation group (Sham), ischemia/reperfusion injury (I/R) group and sevoflurane post-conditioning group (Se). Hematoxylin-eosin (HE) staining was used to observe the inflammatory response in the brain tissue. The levels of TNF-α, IL-1β, IL-6 in serum were measured by ELISA. The mRNA and protein expression of TLR4 and NF-κB p65 were detected by RT-PCR and Western blot in the brain tissue.

RESULTS: The post-conditioning of sevoflurane decreased the level of inflammatory reaction in ischemic-reperfusion rat cerebral infarction area and reduced the levels of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 in rats with ischemia-reperfusion injury. In addition, after treatment with sevoflurane, the mRNA and protein expression of TLR4 and NF-κBp65 in TLR4/NF-κB pathway was inhibited.

CONCLUSIONS: Sevoflurane post-conditioning can decrease the inflammatory reaction in cerebral infarct area induced by cerebral ischemia-reperfusion injury in rats. The neuroprotective effect mechanism of sevoflurane may be related to TLR4/NF-κB signaling pathway.

Free PDF Download

To cite this article

C.-X. Shi, Y.-B. Ding, F. Yu J. Jin, T. Li, J.-H. Ma, L.-Y. Qiao, W.-Z. Pan, K.-Z. Li
Effects of sevoflurane post-conditioning in cerebral ischemia-reperfusion injury via TLR4/NF-κB pathway in rats

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 6
Pages: 1770-1775
DOI: 10.26355/eurrev_201803_14595